Contribution of skeletal muscle to cancer immunotherapy: A focus on muscle function, inflammation, and microbiota
Related Experiment Video
Updated: Aug 24, 2025

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia
Published on: November 30, 2016
Yuanle Deng1, Ling Zhao1, Xuemei Huang1
1Department of Clinical Nutrition, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Sichuan, China.
Abstract:
Sarcopenia, characterized by degenerative and systemic loss of skeletal muscle mass and function, is a multifactorial syndrome commonly observed in individuals with cancer. Additionally, it represents a poor nutritional status and indicates possible presence of cancer cachexia. Recently, with the extensive application of cancer immunotherapy, the effects of sarcopenia/cachexia on cancer immunotherapy, have gained attention. The aim of this review was to summarize the influence of low muscle mass (sarcopenia/cachexia) on the response and immune-related adverse events to immunotherapy from the latest literature. It was revealed that low muscle mass (sarcopenia/cachexia) has detrimental effects on cancer immunotherapy in most cases, although there were results that were not consistent with this finding. This review also discussed potential causes of the paradox, such as different measure methods, research types, muscle indicators, time point, and cancer type. Mechanically, chronic inflammation, immune cells, and microbiota may be critically involved in regulating the efficacy of immunotherapy under the condition of low muscle mass (sarcopenia/cachexia). Thus, nutritional interventions will likely be promising ways for individuals with cancer to increase the efficacy of immunotherapy in the future, for low muscle mass (sarcopenia/cachexia) is an important prognostic factor for cancer immunotherapy.
Insights
Sarcopenia, or low muscle mass, negatively impacts cancer immunotherapy effectiveness and immune-related side effects in most patients. Nutritional interventions may improve immunotherapy outcomes for cancer patients with sarcopenia.
Area of Science:
- Oncology
- Immunology
- Geriatrics
Background:
- Sarcopenia, a loss of muscle mass and function, is common in cancer patients.
- It signifies poor nutritional status and potential cancer cachexia.
- The impact of sarcopenia on cancer immunotherapy is a growing area of research.
Purpose of the Study:
- To review the influence of sarcopenia/cachexia on cancer immunotherapy response.
- To analyze effects on immune-related adverse events.
- To explore potential mechanisms and confounding factors.
Main Methods:
- Literature review of recent studies.
- Analysis of data on sarcopenia/cachexia and immunotherapy outcomes.
- Discussion of inconsistencies and potential explanations.
Main Results:
- Low muscle mass generally has detrimental effects on cancer immunotherapy efficacy.
- Inconsistencies in findings were observed, attributed to varied methodologies.
- Chronic inflammation, immune cells, and microbiota are implicated mechanistically.
Conclusions:
- Sarcopenia is a significant prognostic factor in cancer immunotherapy.
- Nutritional interventions show promise for enhancing immunotherapy efficacy.
- Further research is needed to clarify the complex relationship and optimize interventions.
Related Concept Videos
Tumor Immunotherapy
The Tumor Microenvironment
Disorders of the Skeletal Muscle
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Formation of Muscle Fibers from Myoblasts
Muscle progenitor cells (MPCs) are formed from the myotomes. MPCs express genes that encode the transcription factors Pax3 and Pax7. Along with Pax 3/7, other transcription...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...

